Literature DB >> 1872017

Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine.

B E Johansson1, E D Kilbourne.   

Abstract

Mice were immunized with either inactivated whole virus influenza A (H3N2) virus (WV) vaccine or with purified N2 neuraminidase (NA) vaccine then challenged with mouse-adapted homologous infective virus at intervals of 1-141 days later in order to ascertain the optimal vaccine-infection interval for induction of resistance to subsequent infection. Measured by serological or infection suppressing response, this interval was 15 days for both vaccines. Maximal reduction in pulmonary virus replication during initial (postvaccination) infection was achieved with WV vaccine, but in second infection by NA vaccine. This study provides further support for the concept of infection-permissive immunization with NA vaccines and suggests the promise of programmed antigenic stimulation by coupling of non-replicating and replicating antigens in the induction of solid immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872017     DOI: 10.1016/0264-410x(91)90059-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.

Authors:  B E Johansson; E D Kilbourne
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

2.  Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.

Authors:  E Frobert; M Bouscambert-Duchamp; V Escuret; S Mundweiler; M Barthélémy; F Morfin; M Valette; C Gerdil; B Lina; O Ferraris
Journal:  Curr Microbiol       Date:  2009-12-25       Impact factor: 2.188

Review 3.  Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.

Authors:  Luca T Giurgea; David M Morens; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Vaccines (Basel)       Date:  2020-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.